Your browser doesn't support javascript.
loading
Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review.
Boese, Christoph Kolja; Lechler, Philipp; Frink, Michael; Hackl, Michael; Eysel, Peer; Ries, Christian.
Afiliación
  • Boese CK; Department of Orthopaedic and Trauma Surgery, University Hospital of Cologne, Cologne 50931, Germany. christoph.boese@uk-koeln.de.
  • Lechler P; Clinic for Trauma and Hand Surgery, Kreiskliniken, Altötting 84503, Germany.
  • Frink M; Center for Orthopaedics and Trauma Surgery, University Hospital Giessen and Marburg, Marburg 35043, Germany.
  • Hackl M; Department of Orthopaedic and Trauma Surgery, University Hospital of Cologne, Cologne 50931, Germany.
  • Eysel P; Department of Orthopaedic and Trauma Surgery, University Hospital of Cologne, Cologne 50931, Germany.
  • Ries C; Department of Orthopaedic and Trauma Surgery, University Hospital of Cologne, Cologne 50931, Germany.
World J Clin Cases ; 7(14): 1825-1836, 2019 Jul 26.
Article en En | MEDLINE | ID: mdl-31417928
ABSTRACT

BACKGROUND:

Increasing numbers of total joint arthroplasties and consecutive revision surgery are associated with the risk of periprosthetic joint infections (PPJI). Treatment of PPJI is complex and associated with immense socio-economic burden. One treatment aspect is parenteral antiinfective therapy, which usually requires an inpatient setting [Inpatient parenteral antibiotic therapy (IPAT)]. An alternative is outpatient parenteral treatment [Outpatient parenteral antibiotic therapy (OPAT)]. To conduct a health economic cost-benefit analysis of OPAT, a detailed cost analysis of IPAT and OPAT is required. So far, there is a lack of knowledge on the health economic effects of IPAT and OPAT for PPJI.

AIM:

To review an economic comparison of IPAT and OPAT.

METHODS:

A systematic literature review was performed through Medline following the PRISMA guidelines.

RESULTS:

Of 619 identified studies, 174 included information of interest and 21 studies were included for quantitative analysis of OPAT and IPAT costs. Except for one study, all showed relevant cost savings for OPAT compared to IPAT. Costs for IPAT were between 1.10 to 17.34 times higher than those for OPAT.

CONCLUSION:

There are only few reports on OPAT for PPJI. Detailed analyses to support economic or clinical guidelines are therefore limited. There is good clinical evidence supporting economic benefits of OPAT, but more high quality studies are needed for PPJI.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Guideline / Health_economic_evaluation / Systematic_reviews Idioma: En Revista: World J Clin Cases Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Guideline / Health_economic_evaluation / Systematic_reviews Idioma: En Revista: World J Clin Cases Año: 2019 Tipo del documento: Article País de afiliación: Alemania
...